Intensive Post-Remission Consolidation with G-CSF-Support: Tolerability, Safety, Reduced Hospitalization, and Efficacy of a New Treatment Protocol for AML Patients ≥60 Years
Wolfgang R. Sperr(Medical University of Vienna), Peter Valent(Medical University of Vienna), Thamer Sliwa(Hanusch Hospital), Susanne Herndlhofer(Assistance Publique – Hôpitaux de Paris), Karoline V. Gleixner(Medical University of Vienna), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Michael Girschikofsky(Krankenhaus der Elisabethinen), Klaus Geißler(University of Vienna), Paul Knoebl(Medical University of Vienna), Rainer Poehnl(Kaiser-Franz-Josef-Spital), Karin Strecker(Donauspital), Ansgar Weltermann, Michael Kundi(Medical University of Vienna), Ulrich Jaeger(Medical University of Vienna), Sigrid Machherndl‐Spandl(Krankenhaus der Elisabethinen)
Cited by 1
Related Papers
Estimates of global seasonal influenza-associated respiratory mortality: a modelling study
|The Lancet|2017|3k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Diagnostic criteria and classification of mastocytosis: a consensus proposal
|Leukemia Research|2001|1.1k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
High Plasma Levels of Factor VIII and the Risk of Recurrent Venous Thromboembolism
|New England Journal of Medicine|2000|764